Company intelligence / Profile preview

Iris Molecular Diagnostics

Ownership: Private
Employees: ~300
Development stage: Commercial

Overview

Iris Molecular Diagnostics developed and commercialized the NADiA® ProsVue™, an FDA-cleared immuno-PCR assay to determine the rate of change in serum PSA levels after radical prostatectomy, providing prognostic information on prostate cancer recurrence risk. The technology enabled highly sensitive detection using DNA-labeled antibodies and PCR amplification. The product received FDA clearance and was marketed prior to acquisition.

Therapeutic areas: Oncology
Modalities: Immuno-PCR assayIn-vitro diagnostic assay
Industry: Protein Biomarker Diagnostics

Drug pipeline

2 assets

NADiA ProsVue

NDA

Indications: Prostate cancer monitoring

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Iris Molecular Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Iris Molecular Diagnostics.

Explore the full profile